Clinical trials: Behaviors
Indolent Systemic Mastocytosis
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis
The objective of this study is to compare the safety and efficacy of masitinib (AB1010) to placebo in patients with mastocytosis with handicap.
- Trial name
- AB06006 (NCT00814073)
- Testing
- Masitinib, Best Supportive Care
- Where
- 24 sites in United States, France
- Volunteers
- 135 people
- Sponsor
- AB Science
Attention Deficit Disorder With Hyperactivity
A Study of the Effectiveness and Safety of Prolonged-release Methylphenidate Hydrochloride in Adult Patients With Attention Deficit/Hyperactivity Disorder.
The purpose of this study is to evaluate the effectiveness and safety of three doses of prolonged-release methylphenidate (a central nervous system (CNS) stimulant) in adult patients with attention deficit/hyperactivity disorder…
- Trial name
- NCT00246220
- Testing
- methylphenidate hydrochloride
- Volunteers
- 402 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Pulmonary Disease, Chronic Obstructive
Proof of Concept Study Assessing Technology-Assisted Respiratory Adherence Prototype Version 3 in Individuals With COPD
The study's primary aim is to assess whether there is a clinically significant reduction in breathlessness in symptomatic individuals with chronic obstructive respiratory disease (IwCOPD) following engagement with…
- Trial name
- NCT04795323
- Testing
- TARA v3.1, only non-pharmacological self-management support, TARA v3.2, both non-pharmacological and pharmacological self-management support
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Boehringer Ingelheim
Major Depressive Disorder, Psychotic Disorders
A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00128479
- Testing
- mifepristone, mifepristone 600 mg, mifepristone 1200 mg
- Where
- 44 sites in United States
- Volunteers
- 443 people
- Sponsor
- Corcept Therapeutics
Depressive Disorder, Major, Recurrence
Study Evaluating Venlafaxine ER in Recurrent Depression
The purpose of this study is to review the long-term comparative efficacy of venlafaxine ER in achieving and sustaining remission (wellness) in patients with recurrent major depression
- Trial name
- NCT00046020
- Testing
- Venlafaxine ER
- Volunteers
- 1,096 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder, MDD
Operation of Brain Stimulation Equipment Under Remote Viewing Effectiveness Registry
The goal of this observational study is to record and analyze factors putatively affecting the clinical outcomes among patients undergoing transcranial magnetic stimulation (TMS) treatment for major depressive disorder (MDD) or…
- Conditions
- Major Depressive Disorder, MDD, Generalized Anxiety Disorder, GAD
- Trial name
- OBSERVER (NCT06512324)
- Testing
- Ampa One TMS System
- Where
- 2 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Biomedical Discoveries and Neuroscientific Foundations LLC
Depression
Pipamperone/Citalopram (PipCit)Versus Citalopram in the Treatment of Major Depressive Disorder(MDD)
The primary objective is to demonstrate whether the addition of pipamperone 5 mg twice daily (bd) to citalopram, 40 mg daily in patients suffering from MDD will improve the efficacy of citalopram 40 mg in these patients.
- Trial name
- NCT00672659
- Testing
- Citalopram + Pipamperone, Citalopram
- Where
- United Kingdom
- Volunteers
- 165 people
- Sponsor
- PharmaNeuroBoost N.V.
Pharmacokinetics, Bioavailability
An Investigation Of The Effects Of Food On The Absorption Of A Varenicline Controlled Release Formulation
1. To estimate the absorption of a single oral dose of a controlled release varenicline tablet under fed and fasted conditions. 2.
- Conditions
- Pharmacokinetics, Bioavailability, Smoking Cessation
- Trial name
- NCT00731562
- Testing
- Varenicline Tartrate Controlled Release
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Adult Attention Deficit Hyperactivity Disorder
Open-label Safety Study in Adults With ADHD
To evaluate the long-term safety and tolerability of SEP 225289 in adult subjects with Attention Deficit Hyperactivity Disorder (ADHD)
- Trial name
- NCT02160262
- Testing
- Dasotraline
- Where
- 65 sites in United States
- Volunteers
- 724 people
- Sponsor
- Sumitomo Pharma America, Inc.
Low Back Pain
Online Cognitive Behavioral Therapy (CBT) Workbook
This research will evaluate the efficacy of a new online self- help intervention, the Wellness Workbook, for individuals with chronic low back pain (CLBP).
- Trial name
- WW (NCT01337843)
- Testing
- Wellness Workbook, Pain Management Print Materials
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- Talaria, Inc
Prescription Drug Abuse, Substance Abuse
A High School Program for Preventing Prescription Drug Misuse
This project will develop and evaluate a program to prevent prescription drug misuse in high school students
- Conditions
- Prescription Drug Abuse, Substance Abuse, Substance Use (Drugs, Alcohol)
- Trial name
- NCT03219190
- Testing
- LST High School Hybrid
- Where
- United States
- Volunteers
- 1,804 people, healthy volunteers welcome
- Sponsor
- National Health Promotion Associates, Inc.
Neuralgia Peripheral, Neuropathic Pain
Preferences in Pain Treatment: A Discrete Choice Experiment in Patients With Peripheral Neuropathic Pain (pNP)
The objective of this study is to identify and weight attributes of topic and systemic pain treatment options relevant from the patients' perspective with peripheral neuropathic pain.
- Conditions
- Neuralgia Peripheral, Neuropathic Pain, Patient Preference
- Trial name
- DExPri (NCT04184596)
- Testing
- Discrete Choice Experiment
- Where
- 3 sites in Germany
- Volunteers
- 153 people
- Sponsor
- LinkCare GmbH
Smoking Cessation
ASIA CHOICES CHampix (Varenicline) Observational Investigation in the CEssation of Smoking
The purpose of this study is to describe the characteristics of the smoker who wants to quit and his/her treating physician, in addition to determine the safety and effectiveness of Champix in the real-world setting of smokers in…
- Trial name
- ASIA CHOICES (NCT00808015)
- Testing
- varenicline
- Where
- 97 sites in China, India and 2 more
- Volunteers
- 1,373 people
- Sponsor
- Pfizer
Aging
Improvement in Memory With Plasticity-Based Adaptive Cognitive Training (IMPACT)
The primary objective of this study is to evaluate the effects of a computer-based training program on the memory and cognitive abilities of mature individuals undergoing healthy aging.
- Trial name
- IMPACT (NCT00283010)
- Testing
- Computerized Plasticity-Based Adaptive Cognitive Training, Educational DVDs
- Where
- United States
- Volunteers
- 487 people, healthy volunteers welcome
- Sponsor
- Posit Science Corporation
Electronic Cigarette Use
Nicotine Uptake, Measures of Abuse Liability, and Puffing Topography With Use of RELX ENDS Products by Smokers
This study is being conducted to evaluate nicotine uptake and exposure, the abuse liability, and puffing topography associated with the use of an electronic nicotine delivery system ENDS with tobacco- and menthol-flavored…
- Trial name
- NCT04640285
- Testing
- RELX ENDS Tobacco Flavor, RELX ENDS Menthol Flavor, Usual Brand Cigarette
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Cheerain HK Limited
Chronic Obstructive Pulmonary Disease (COPD)
Validation of Questionnaire and Assessment of Patient Satisfaction for Budesonide/Formoterol Fix Combination Dry Powder Inhalers (DPI) in Chronic Obstructive Pulmonary Disease (COPD)
The aim of this study is to describe patient preferences on budesonide/formoterol fix dose combination for the treatment of their COPD, and to find those factors more strongly associated to a better attitude to medication.
- Trial name
- NCT01646424
- Where
- 20 sites in Turkey (Türkiye)
- Volunteers
- 446 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Impact of a Digital Self-Management Program on A1C for Individuals With Type 2 Diabetes
The goal of this study is to evaluate a digital chronic disease self-management program designed to provide virtual support and guidance for patients with type 2 diabetes.
- Trial name
- NCT04892680
- Testing
- Online Diabetes Self-Management Education and Support (DSMES) Program
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Omada Health, Inc.
Attention Deficit Hyperactivity Disorder
Phase 3 Randomized Double-Blind Placebo-Controlled Study of NRP104 in Children Aged 6-12 With ADHD
This study is designed to assess efficacy and safety of NRP-104 administered as a daily dose of 30mg, 50mg or 70mg compared to placebo in the treatment of children aged 6-12 years with ADHD.
- Trial name
- NCT00556296
- Testing
- NRP104
- Volunteers
- 297 people
- Sponsor
- New River Pharmaceuticals
Attention Deficit Disorder With Hyperactivity
Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Trial 42603ATT3004 is an open-label extension study to clinical trial 42603ATT3002 (NCT00246220). In trial 42603ATT3002 the efficacy and safety of OROS methylphenidate was assessed in adult subjects with Attention Deficit…
- Trial name
- NCT00307684
- Testing
- double blind PR OROS methylphenidate, open label PR OROS methylphenidate
- Where
- 21 sites in France, Germany and 5 more
- Volunteers
- 155 people
- Sponsor
- Janssen-Cilag International NV
Dehydration
Transdermal Optical Imaging (TOI) as a Non-invasive Measure to Detect Changes in Hydration Status in Healthy Adults and Athletes
The primary objective of this study is to analyze smart phone-based Transdermal Optical Imaging (TOI) features to develop a model that can discern hydration status, including: 1) at various timepoints throughout a 24-hour period…
- Trial name
- NCT06212518
- Testing
- GENPOP ad libitum fluid intake, GENPOP fluid restriction, ATHLETE ad libitum fluid intake
- Where
- 4 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D